Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$7.52 USD
-0.17 (-2.21%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $7.53 +0.01 (0.13%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Astria Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ATXS 7.52 -0.17(-2.21%)
Will ATXS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATXS
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
Other News for ATXS
ATXS forms 20 Day Moving Average Support on October 3
Is ATXS gathering momentum? Bollinger Band Squeeze shows up after advancing 1.99%
Astria Therapeutics (ATXS) Advances Phase 3 Trial for Hereditary Angioedema Treatment
Is ATXS showing upside potential? Crossed Above 20 Day Moving Average shows up after gaining 3.57%
Astria Therapeutics begins enrollment in EU for ALPHA-ORBIT trial